Eureka Research: News and Highlights!

Eureka Newsletter

Please send us your questions about the study so we can answer them in our upcoming webinars and podcasts: Click here. We want to hear from you!

Do you have a Fitbit or a MyChart account?
You can now automatically share data from your health devices as well as your online health records with the COVID-19 Citizen Science study! This makes it easier than ever to contribute to discoveries. Be on the lookout for a text message on how to share your data!

As you have seen in this and other newsletters, we have been hard at work building the Eureka Research platform with more features and improved experience for participants.  We are now running over 50 research studies with over 500,000 participants.  We are excited to bring those new features and better experience to our Health eHeart participants and have been working hard to redesign the Health eHeart Study to include improvements like:

• Shorter and simpler study activities (eVisits)
• Ability to participate in Health eHeart using our Eureka mobile app for a better experience
• Connect your medical records and other wearable devices to provide more data automatically
• And more……

Stay tuned for announcements as we get closer to release the new version.

Since the COVID-19 pandemic began in March 2020, testing for SARS-CoV-2 was the first line of defense to slow the virus from spreading.  However, since this was a novel virus, no tests existed to quickly identify people who were infected with SARS-CoV-2. So, the National Institute of Health (NIH) created the RADx consortium to quickly perform clinical trials for new SARS-CoV-2 diagnostic tests and tasked Eureka with developing the web and mobile app infrastructure to run these clinical trials.

Over the past two years, Eureka and RADx conducted 6 studies on 4 SARS-CoV-2 devices:

1. ClearDetect antigen home test from Maxim Bio.
2. Sal6830 saliva test, the nation’s first point of care PCR saliva test for COVID-19, from MicroGEM.
3. Accula accelerated PCR test from Mesa Biotech Inc.
4. Simoa antigen test from Quanterix.

All 4 devices received an Emergency Use Authorization (EUA) from the FDA. Additionally, the RADx studies have resulted in the publication of over 30 academic publications.

In total, the RADx studies enrolled over 15,000 participants. Over 1,700 of these participants participated in the Test Us Bank biorepository study in which blood, saliva, and/or nasal swab samples were collected and stored for future studies so that we will be better prepared for future obstacles that this pandemic (or future pandemics) may present us.

Since Eureka is an online platform, we had the ability to quickly enroll participants into these trials at a pace that far exceeds most traditional clinical trials. While a traditional clinical trial can hope to enroll 350 participants over the course of ~8 weeks, RADx was able to enroll the same number of participants in only 3 days! Since enrollment is online, we were able to enroll participants in remote regions of the country who may not otherwise be able to access SARS-CoV-2 tests. Additionally, the remote nature of these studies limited the amount of person-to-person contact between participants and researchers, which was of vital importance during the pandemic.

We would like to thank our collaborators at the University of Massachusetts, UMASS Lowell, Northwestern University, Johns Hopkins University, Kansas University, University of Iowa, Emory, Oregon Health and Sciences University, and all of our participants who helped accomplish these extraordinary goals.

Our mailing address is:

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.